IRLAB Q3 2024: Several catalysts ahead - Redeye
Bildkälla: Stockfoto

IRLAB Q3 2024: Several catalysts ahead - Redeye

Redeye returns following IRLAB's Q3 report and recent news in the company. We largely reiterate our stance and conclude that the company has several important catalysts ahead - including a Pirepemat phase IIb readout.

Redeye returns following IRLAB's Q3 report and recent news in the company. We largely reiterate our stance and conclude that the company has several important catalysts ahead - including a Pirepemat phase IIb readout.
Börsvärldens nyhetsbrev
ANNONSER